ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

The revision follows Sarepta's announcement of a major collaboration with Arrowhead Pharmaceuticals (NASDAQ:ARWR) that significantly expands its product pipeline. Sarepta Therapeutics disclosed its ...

In other recent news, Sarepta Therapeutics has been making significant strides in its business operations. The company recently announced a substantial collaboration agreement with Arrowhead ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps ... on the large collaboration deal announced with Sarepta (SRPT) (SPRT) and implications for its own ...